Focused ultrasound to open the blood brain barrier, tested with standard immune therapy for lung cancer that spread to the brain

Official title: Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether focused ultrasound can safely open the blood brain barrier in people getting standard immune therapy for lung cancer that spread to the brain.

Read our full plain-language summary

What the trial team says

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT05317858
Stage of testing
Phase 3
Conditions studied
Brain Tumor, Non Small Cell Lung Cancer

Where it is running

This trial lists 14 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.